Education
About Us
Working with TipRanks
Follow Us
Vivoryon Therapeutics AG (NL:VVY)
:VVY
Top Page
Vivoryon Therapeutics AG
(VVY)
Select Model
Select Model
Rating:42Neutral
Price Target:
€1.50
▲(3.45% Upside)
The score is primarily constrained by weak financial performance (zero revenue, large ongoing losses, and significant cash burn) and a deteriorating equity base despite low debt. Technical indicators reinforce the negative setup, with the stock trading below key moving averages and bearish momentum readings. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Vivoryon Therapeutics AG (VVY) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€46.20M
Dividend YieldN/A
Average Volume (3M)31.39K
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue GrowthN/A
EPS GrowthN/A
CountryNL
Employees14
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,614,338
10 Day Avg. Volume27,146
30 Day Avg. Volume31,394
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)6.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vivoryon Therapeutics AG Business Overview & Revenue Model
Company DescriptionVivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
How the Company Makes Money
Vivoryon Therapeutics AG Earnings Call Summary
Earnings Call Date:Sep 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical and financial progress, particularly in reducing expenses and advancing the varoglutamstat program, while also addressing challenges such as a reduced cash position and the need for additional financing for future studies.Q2-2025 Updates
Positive Updates
Significant Reduction in R&D Expenses
Research and development expenses decreased by EUR 7.5 million, from EUR 10.3 million in the first half of 2024 to EUR 2.8 million in the first half of 2025, largely due to a decrease in clinical development and production costs.
Net Loss Reduction
The company reported a net loss of EUR 5.5 million for the first half of 2025, compared to EUR 13.6 million for the first half of 2024, indicating improved financial management.
Strong Clinical Data for Varoglutamstat
Varoglutamstat demonstrated statistically significant and clinically meaningful improvements in kidney functions in Phase II studies, with notable benefits in diabetic kidney disease patients.
New U.S. Patent for Varoglutamstat
Vivoryon secured a new U.S. composition of matter patent for varoglutamstat, supporting market exclusivity through 2044 with potential for extension.
Preclinical Success in Diabetic Kidney Disease Model
Varoglutamstat showed impressive reductions in inflammation and fibrosis in a diabetic kidney disease mouse model.
Positive Feedback from Scientific Community
The data presented at the European Renal Association Annual Congress and ASN Kidney Week were well received by the nephrology community, increasing interest in varoglutamstat.
Negative Updates
Decreased Cash Position
Vivoryon's cash and cash equivalents decreased to EUR 4.8 million as of June 30, 2025, from EUR 9.4 million at the end of 2024, raising concerns about future funding.
Pending Financing for Phase IIb Study
The initiation of a dedicated Phase IIb study for varoglutamstat in diabetic kidney disease patients is contingent on securing additional financing.
Temporary Change in CFO Position
Anne Doering, the CFO, announced a temporary partial leave of absence due to a family health matter, with Marcus Irsfeld stepping in as acting CFO.
Company Guidance
In the recent call discussing Vivoryon's first half 2025 results, several key metrics and achievements were highlighted. Research and development expenses for the period were EUR 2.8 million, a significant reduction from EUR 10.3 million in the first half of 2024, primarily due to decreased clinical development costs and production expenses. General and administrative expenses also saw a decline to EUR 2.8 million from EUR 3.5 million in the previous year. Consequently, the net loss for the first half of 2025 was reduced to EUR 5.5 million, compared to EUR 13.6 million in the same period of 2024. The company reported holding EUR 4.8 million in cash and cash equivalents as of June 30, 2025, with a cash runway extending into January 2026, excluding funds from a standby equity purchase agreement. Vivoryon also secured U.S. patents for varoglutamstat, ensuring market exclusivity through 2044. The company presented compelling kidney function data from its Phase II studies at the European Renal Association Annual Congress, showcasing statistically significant improvements in kidney function with varoglutamstat compared to placebo. Preparations for a dedicated Phase IIb study in diabetic kidney disease are underway, highlighting Vivoryon's strategic focus on expanding its therapeutic impact in the kidney disease market.Vivoryon Therapeutics AG Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | -3.62M | 0.00 | 10.76M | 0.00 |
| Gross Profit | -147.00K | -147.00K | -3.10M | -161.00K | 9.03M | -146.00K |
| EBITDA | -12.34M | -20.34M | -28.35M | -28.17M | -12.03M | -16.34M |
| Net Income | -12.48M | -20.57M | -28.34M | -28.16M | -12.65M | -16.51M |
Balance Sheet | ||||||
| Total Assets | 6.42M | 11.28M | 30.83M | 31.38M | 24.52M | 29.75M |
| Cash, Cash Equivalents and Short-Term Investments | 4.84M | 9.37M | 28.58M | 26.55M | 14.66M | 26.31M |
| Total Debt | 72.00K | 102.00K | 38.00K | 132.00K | 224.00K | 314.00K |
| Total Liabilities | 3.24M | 3.40M | 4.55M | 4.87M | 7.96M | 3.53M |
| Stockholders Equity | 3.18M | 7.88M | 26.28M | 26.51M | 16.56M | 26.22M |
Cash Flow | ||||||
| Free Cash Flow | -10.38M | -19.18M | -22.05M | -21.81M | -11.29M | -14.65M |
| Operating Cash Flow | -10.37M | -19.17M | -21.54M | -21.79M | -11.26M | -14.01M |
| Investing Cash Flow | -6.00K | 10.00M | -10.51M | -13.00K | -28.00K | -640.00K |
| Financing Cash Flow | -57.00K | -57.00K | 24.16M | 33.38M | -827.00K | -90.00K |
Vivoryon Therapeutics AG Peers Comparison
UnderperformOutperform
Sector (55)
NL:VVY
Vivoryon Therapeutics AG
1.56
-0.44
-22.00%
PHGUF
Pharming Group
1.78
0.84
90.86%
GB:0JXZ
Galapagos
28.56
4.38
18.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.